Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Recruiting 5Active not recruiting 5Withdrawn 3Unknown 2Terminated 2Not yet recruiting 1

Sponsor Class

OTHER 2OTHER_GOV 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2Gastrointestinal 1Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 2Gastrointestinal Neoplasms 1Breast Neoplasms 1

Interventions

Cisplatin 352Oxaliplatin 262Capecitabine 258Radiotherapy 240Gemcitabine 223Docetaxel 223Carboplatin 223Drug Therapy 219Cyclophosphamide 219Paclitaxel 205apatinib 201Bevacizumab 196camrelizumab 190Fluorouracil 188sintilimab 133Irinotecan 125Blood Specimen Collection 125Dexamethasone 123Etoposide 119Radiosurgery 118toripalimab 117Surgical Procedures, Operative 115pembrolizumab 112Pemetrexed 108anlotinib 105S 1 (combination) 105Leucovorin 102Surveys and Questionnaires 101Nivolumab 98tislelizumab 96

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Unknown × OTHER × brigatinib × Clear all
NCT04591431 2023-10-03

ROME

Fondazione per la Medicina Personalizzata

Phase 2 Unknown
400 enrolled
BreastGastrointestinalThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Gastrointestinal Neoplasms

NCT05361564 2022-05-04

A Window of Opportunity Study for Investigating Drug Tolerant Persister (DTP) to Preoperative Brigatinib in Resectable Non-small Cell Lung Cancer (NSCLC) Harboring ALK Fusions.

Yonsei University

Phase 2 Unknown
12 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡